Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2015 Dec;94(52):e2341.
doi: 10.1097/MD.0000000000002341.

Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment

Adnan Aydiner  1 , Fatma Sen, Makbule Tambas, Rumeysa Ciftci, Yesim Eralp, Pinar Saip, Hasan Karanlik, Merdan Fayda, Seden Kucucuk, Semen Onder, Ekrem Yavuz, Mahmut Muslumanoglu, Abdullah Igci
Affiliations
Observational Study

Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment

Adnan Aydiner et al. Medicine (Baltimore). 2015 Dec.

Abstract

Metaplastic breast carcinoma (MBC) differs from classic invasive ductal carcinomas regarding incidence, pathogenesis, and prognosis. The purpose of this study was to compare patients with MBC with clinicopathologic and treatment-matched patients with triple-negative breast carcinoma (TNBC) in terms of response to treatment, progression, and survival.Fifty-four patients with MBC and 51 with TNBC, who were treated at Istanbul University, Institute of Oncology, between 1993 and 2014, were included in the study. After correctly matching the patients with 1 of the 2 groups, they were compared to determine differences in response to treatment, disease progression, clinical course, and survival.At a median follow-up of 28 months, 18 patients (17.1%) died and 27 (25.5%) had disease progression. Metaplastic histology was significantly correlated with worse 3-year progression-free survival (PFS) (51 ± 9% vs. 82 ± 6%, P = 0.013) and overall survival (OS) (68 ± 8% vs. 94 ± 4%, P = 0.009) compared with TNBC histology. Patients who received taxane-based chemotherapy (CT) regimens or adjuvant radiotherapy had significantly better PFS (P = 0.002 and P < 0.001) and OS (P < 0.001 and P < 0.001) compared with others. In the multivariate analysis, MBC (hazard ratio [HR]: 0.09, P < 0.001), presence of neoadjuvant chemotherapy (NACT) (HR: 12.8, P = 0.05), and metastasis development at any time during the clinical course (HR: 38.7, P < 0.001) were significant factors that decreased PFS, whereas metastasis development was the only independent prognostic factor of OS (HR: 23.8, P = 0.009).MBC is significantly correlated with worse PFS and OS compared with TNBC. Patients with MBC are resistant to conventional CT agents, and more efficient treatment regimens are required.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Progression-free survival curves of metaplastic and triple-negative breast cancer patients.
FIGURE 2
FIGURE 2
Overall survival curves of metaplastic and triple-negative breast cancer patients.
See this image and copyright information in PMC

References

    1. Pezzi CM, Patel-Parekh L, Cole K, et al. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol 2007; 14:166–173. - PubMed
    1. Al Sayed AD, El Weshi AN, Tulbah AM, et al. Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors. Acta Oncol 2006; 45:188–195. - PubMed
    1. Huvos AG, Lucas JC, Jr, Foote FW., Jr Metaplastic breast carcinoma. Rare form of mammary cancer. N Y State J Med 1973; 73:1078–1082. - PubMed
    1. Tavassoli FDP. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003.
    1. Kumar V, Abbas AK, Aster JC, et al. Robbins and Cotran Pathologic Basis of Disease. 8th ed.Philadelphia, PA; USA: Elsevier; 2010.

Publication types

MeSH terms